title: [Survivin expression in midline T-cell lymphoma in relation to Epstin-Barr virus infection].
abstract: To investigate the expression of survivin gene and its relationship with Epstin-Barr virus (EBV) infection in midline T-cell lymphoma (MTL), immunohistochemistry staining method was used to examine the expression of survivin and EBV-latent membrane protein (LMP-1) in the 41 cases. In situ hybridization (ISH) was used to detect EBV-encoded RNA (EBER1/2). The results showed that the expression of survivin was positive in 26 cases of midline T-cell lymphoma, but no positive was detected in 10 cases of reactive lymphoid tissues. The positive expression ratio of survivin was 12.5% in cases of MTL with low grade of malignancy, and was 75.76% in cases of MTL with middle and high grades of malignancy, the significant difference was found between these two groups (chi(2) = 8.55, P < 0.01). Positive expression ratios of EBER1/2 and LMP-1 were 70.73% and 41.46% respectively. Survivin expression was not significantly different between EBER1/2 positive and negative cases (P > 0.05). It is concluded that survivin expression is up-regulated in MTL, and survivin positive expression rate is associated with the degree of malignancy. Survivin may play a role in the pathogenesis of the MTL by influencing cell apoptosis. EBV infection is not significantly associated with survivin expression in the MTL.
authors.affiliation: Department of Pediatrics, Taihe Hospital, Yunyang Medical College, Shiyan 442000, China. mingmeng1992@yahoo.com.cn
authors.forename: Meng
authors.initials: M
authors.lastname: Ming
authors.forename: Da-Bin
authors.initials: DB
authors.lastname: Wang
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Yi
authors.forename: Dian-Ding
authors.initials: DD
authors.lastname: Zou
authors.forename: Jun-Xia
authors.initials: JX
authors.lastname: Yao
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003598:Cytoskeletal Proteins; D020031:Epstein-Barr Virus Infections / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D005260:Female; D006103:Granuloma, Lethal Midline / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D051034:Inhibitor of Apoptosis Proteins; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D060588:LIM Domain Proteins; D016399:Lymphoma, T-Cell / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009669:Nose Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D012367:RNA, Viral / Q000235:genetics; D000077022:Survivin
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C107489:BIRC5 protein, human; D003598:Cytoskeletal Proteins; C099537:Epstein-Barr virus encoded RNA 1; C106732:Epstein-Barr virus encoded RNA 2; D051034:Inhibitor of Apoptosis Proteins; D047908:Intracellular Signaling Peptides and Proteins; D060588:LIM Domain Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; C484380:PDLIM7 protein, human; D012367:RNA, Viral; D000077022:Survivin